Triple-agonist research peptide targeting GLP-1, GIP and glucagon receptors.
Retatrutide is a novel triple receptor agonist under investigation for its multi-pathway effects on metabolic regulation.
Simultaneous agonism of GLP-1R, GIP-R and glucagon receptors modulates insulin sensitivity, satiety signaling and energy expenditure.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
Randomized, double-blind, placebo-controlled phase 2 of retatrutide across multiple dose cohorts in adults with obesity (BMI ≥30).
Up to −24.2% mean body weight at 12 mg; dose-dependent reductions in waist circumference and lipids.
Compared retatrutide to placebo and dulaglutide on HbA1c, weight and metabolic markers in T2D.
HbA1c reductions up to 2.0% and weight loss up to 16.9% at top dose vs. comparators.
Characterized LY3437943 receptor engagement and metabolic effects ahead of clinical trials.
Demonstrated additive effect of glucagon arm on energy expenditure and lipid mobilization.
Lyophilized at -20°C. Protect from light. Reconstitute with bacteriostatic water for short-term studies.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — Retatrutide is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
